Browse the evidence

Alabama participants had more favorable scores for hedonic eating at baseline and maintained these scores at week 16 compared to Colorado participants.

Understanding hedonic eating can help tailor interventions to improve weight loss outcomes.

Exercise training did not induce further improvements in lean mass in either the supplement or placebo group.

Exercise alone may not be sufficient to increase lean mass in older adults if they are already using effective nutritional supplements.

There are trivial hypertrophic effects between proximal, mid-belly, and distal muscle sites.

Trivial differences in hypertrophy suggest that exercise selection may not need to prioritize specific muscle lengths.

The 'Competition Model of Metabolism' explains stability of physiological states despite metabolic perturbations.

Recognizing the mechanisms behind stability can inform interventions for weight management.

There is a strong imperative to assess the health effects of sugar-sweetened beverages as the burden of noncommunicable diseases increases.

Increased research on sugar-sweetened beverages is necessary to inform public health policies.

GLP-1 receptor agonists may modify aortic disorders through anti-inflammatory, antioxidant, and antiatherogenic properties.

GLP-1 RAs could be considered for patients with aortic disorders due to their beneficial properties.

High protein diets do not confer additional satiating benefits in resistance-trained individuals during short-term energy deficit.

Practitioners should consider that increasing protein intake beyond moderate levels may not enhance satiety in resistance-trained individuals on a calorie deficit.

The three evaluated accelerometers provided estimates of total energy expenditure (TEE) differing significantly from TEE measured by doubly labeled water (DLW), with differences ranging from -690 to 220 kcal/d.

Practitioners should be cautious when using these accelerometers for TEE estimation as they may not provide fully accurate results.

Regression equations generated from accelerometer-assessed TEE accounted for 46-74% of the variability in DLW-measured TEE.

The accelerometers can provide a reasonable estimate of TEE variability, but should be used with caution.

Habitual sleep duration did not alter overfeeding-mediated body weight gain, fat gain, and fat distribution.

Sleep duration may not influence weight or fat gain during overfeeding.

Metabolic drugs such as GLP-1-based therapies and SGLT2 inhibitors have benefits that extend beyond metabolic improvements into changes in chronic inflammation.

Practitioners should consider the anti-inflammatory potential of metabolic drugs in clinical settings.

Physical frailty and sarcopenia are associated with morbidity and 2-fold mortality in patients with advanced chronic liver disease awaiting liver transplantation.

Healthcare providers should assess frailty and sarcopenia in liver transplant candidates to improve outcomes.

Early identification of physical frailty in the liver transplantation clinical pathway is essential for targeted interventions.

Clinicians should implement screening tools for frailty in liver transplant candidates to tailor interventions.

Transient reductions in fasting glucose were observed in participants with T2D, but these were not sustained and not significantly different from placebo at day 29.

While LY3537021 may reduce fasting glucose, the effects may not be long-lasting.

The evidence supporting GLP-1RAs for treating PsO and PsA remains limited.

Further clinical research is needed to establish the efficacy and safety of GLP-1RAs for PsO and PsA.

Environmental cues such as chronic cold exposure, exercise, and caloric restriction potentiate adipocyte browning.

Incorporating cold exposure, exercise, and caloric restriction may enhance browning and its benefits.

Loss of muscle-related indices exceeded prespecified benchmarks in two thirds of incretin-based interventions.

Clinicians should monitor muscle mass when prescribing incretin therapies for weight loss.

High-dose canagliflozin (300 mg/day) is significantly associated with reduced sepsis risk versus control.

Practitioners may consider high-dose canagliflozin as a safer option regarding sepsis risk.

Treatment duration had minimal influence on primary outcomes.

Practitioners may not need to adjust treatment duration based on infection risk concerns.

All active treatments, including Dapagliflozin 10 mg, Survodutide, Tirzepatide, and higher-dose Semaglutide, improved fibrosis versus placebo.

Practitioners can consider these anti-diabetic agents as effective options for improving liver fibrosis in patients with MASH.

Dose-dependent effects were more prominent for MASH resolution than fibrosis improvement.

Practitioners should consider the dosage of anti-diabetic agents when aiming for MASH resolution.

GLP-1 receptor agonists can induce psychiatric side effects such as increased impulsivity, dysphoria, and aggression.

Physicians should be cautious of potential psychiatric side effects when prescribing GLP-1 RAs.

The psychiatric side effects resolved with medication cessation.

Discontinuation of GLP-1 RAs may alleviate associated psychiatric symptoms.

There may be a relationship between GLP-1 receptor agonists and mood.

Further investigation is warranted to understand the mood-related effects of GLP-1 RAs.